Free Light Chains & Monoclonal Gammopathies
Impact on Diagnostic Panels
Intact Immunoglobulin/Free Light Chain
August 2008
In 2002 an assay for free light chain quantitation became available. These antisera do not bind the light chain contained in intact immunoglobulins. They recognize epitopes on light chains that are hidden within the binding to the heavy chains.
When the light chains are in solution and not bound to heavy chain these epitopes are available and can be quantitated. There are two separate assays, one for kappa free light chain and one for lambda free light chain and they each have their reference range. In addition the kappa lambda free light chain ratio has a reference range, and this is useful diagnostically. If this ratio was high, it implies a clonal expansion of cells producing kappa free light chain and conversely if it’s low, it suggests an expansion of lambda-producing cells.
Intact Immunoglobulin/ Free Light Chain |
Jump to section:
- Introduction
- Diagnostic Tests
- Mayo Clinic 1960-2003
- Plasma Cell Proliferative Disorders
- Serum Protein Electrophoresis & Immunofixation Electrophoresis
- Serum Protein Electrophoresis & Immunofixation Electrophoresis
- Monoclonal Serum Proteins: Newly Diagnosed Multiple Myeloma (n=1027)
- Serum Protein Electrophoresis & Immunofixation Electrophoresis
- Urine Protein Electrophoresis & Immunofixation Electrophoresis
- Intact Immunoglobulin/Free Light Chain
- FLC Reference Range
- Diagnoses for 428 Patients Selected for Urine Monoclonal Protein
- Serum PEL & IFE Results: 428 Pts with Urine Monoclonal Protein
- Laboratory Results: 428 Patients with Monoclonal Urinary Protein
- Potential Savings
- Uses of Serum Free Light Chain Assay
- Diagnostic Test Panel for Suspected Monoclonal Gammopathies
- Questions?
External
link
PDF
document
Excel
document
Word
document